nach oben

Der Nervenarzt

Erschienen in:

01.06.2015 | Leitthema

Auf dem Weg zu mehr Präzision in der Hirntumortherapie

Möglichkeiten und Grenzen der MR-Bildgebung

verfasst von: Dr. A. Radbruch, E. Hattingen

Erschienen in: Der Nervenarzt | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Zusammenfassung

Durch die Einführung funktioneller Magnetresonanz(MR)-Sequenzen hat sich der Stellenwert der MR-Bildgebung in der Neuroonkologie in den letzten Jahren massiv erhöht. Beschränkte sich die MR-Bildgebung bei Hirntumoren früher zumeist auf die kontrastmittelverstärkte T1-gewichteten MR-Sequenzen, so können heute mithilfe der funktionellen Sequenzen unmittelbar pathophysiologische Aspekte des Tumorwachstums visualisiert und untersucht werden. In dem Artikel werden die für die neuroonkologische Bildgebung relevanten MR-Sequenzen, pathophysiologische Hintergründe sowie potenzielle Anwendungen in der Klinik vorgestellt. Zuletzt wagen wir einen Ausblick auf künftige Entwicklungen mit den Möglichkeiten der Ultrahochfeld-MRT.

Ellingson BM et al (2014) Pros and cons of current brain tumor imaging. Neuro Oncol 16(Suppl 7):vii2–vii11 PubMedCrossRef

Niendorf HP et al (1987) Dose administration of gadolinium-DTPA in MR imaging of intracranial tumors. AJNR Am J Neuroradiol 8(5):803–815 PubMed

Nowosielski M et al (2014) Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology 82(19):1684–1692 PubMedCrossRef

Bahr O et al (2014) Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma. Neurology 83(3):227–234 PubMedCrossRef

Bahr O et al (2011) Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma. Neuro Oncol 13(9):1020–1029 PubMedCentralPubMedCrossRef

Wen PY et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963–1972 PubMedCrossRef

Macdonald DR et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8(7):1277–1280 PubMed

Radbruch A et al (2012) Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria. Neuro Oncol 14(2):222–229 PubMedCentralPubMedCrossRef

Gupta RK et al (2000) Relationships between choline magnetic resonance spectroscopy, apparent diffusion coefficient and quantitative histopathology in human glioma. J Neurooncol 50(3):215–226 PubMedCrossRef

10.

Herminghaus S et al (2002) Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors. NMR Biomed 15(6):385–392 PubMedCrossRef

11.

Kinoshita Y, Yokota A (1997) Absolute concentrations of metabolites in human brain tumors using in vitro proton magnetic resonance spectroscopy. NMR Biomed 10(1):2–12 PubMedCrossRef

12.

Kovanlikaya A et al (2005) Untreated pediatric primitive neuroectodermal tumor in vivo: quantitation of taurine with MR spectroscopy. Radiology 236(3):1020–1025 PubMedCrossRef

13.

Senft C et al (2009) Diagnostic value of proton magnetic resonance spectroscopy in the noninvasive grading of solid gliomas: comparison of maximum and mean choline values. Neurosurgery 65(5):908–913 (discussion 913) PubMedCrossRef

14.

Moller-Hartmann W et al (2002) Clinical application of proton magnetic resonance spectroscopy in the diagnosis of intracranial mass lesions. Neuroradiology 44(5):371–381 PubMedCrossRef

15.

Graves EE et al (2001) Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. AJNR Am J Neuroradiol 22(4):613–624 PubMed

16.

Hattingen E et al (2008) Prognostic value of choline and creatine in WHO grade II gliomas. Neuroradiology 50(9):759–767 PubMedCrossRef

17.

Hattingen E et al (2009) 1H MR spectroscopic imaging with short and long echo time to discriminate glycine in glial tumours. MAGMA 22(1):33–41 PubMedCrossRef

18.

Choi C et al (2012) 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 18(4):624–629 PubMedCentralPubMedCrossRef

19.

Schumacher T et al (2014) A vaccine targeting mutant IDH1 induces antitumour immunity. Nature 512(7514):324–327 PubMedCrossRef

20.

Hattingen E et al (2013) Phospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapy. PLoS One 8(3):e56439 PubMedCentralPubMedCrossRef

21.

Esmaeili M et al (2014) IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma. Cancer Res 74(17):4898–4907 PubMedCrossRef

22.

Law M et al (2004) Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 25(5):746–755 PubMed

23.

Law M et al (2008) Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 247(2):490–498 PubMedCentralPubMedCrossRef

24.

Lev MH et al (2004) Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 25(2):214–221 PubMed

25.

Saito T et al (2012) Role of perfusion-weighted imaging at 3T in the histopathological differentiation between astrocytic and oligodendroglial tumors. Eur J Radiol 81(8):1863–1869 PubMedCrossRef

26.

Boxerman JL, Schmainda KM, Weisskoff RM (2006) Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 27(4):859–867 PubMed

27.

Law M et al (2006) Comparing perfusion metrics obtained from a single compartment versus pharmacokinetic modeling methods using dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 27(9):1975–1982 PubMed

28.

Vidiri A et al (2012) Early perfusion changes in patients with recurrent high-grade brain tumor treated with Bevacizumab: preliminary results by a quantitative evaluation. J Exp Clin Cancer Res 31:33 PubMedCentralPubMedCrossRef

29.

Kickingereder P et al (2014) Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging. Radiology 272(3):843–850 PubMedCrossRef

30.

Blasel S et al (2010) Elevated peritumoural rCBV values as a mean to differentiate metastases from high-grade gliomas. Acta Neurochir (Wien) 152(11):1893–1899

31.

Stecco A et al (2011) DTI and PWI analysis of peri-enhancing tumoral brain tissue in patients treated for glioblastoma. J Neurooncol 102(2):261–271 PubMedCrossRef

32.

Hakyemez B et al (2010) Solitary metastases and high-grade gliomas: radiological differentiation by morphometric analysis and perfusion-weighted MRI. Clin Radiol 65(1):15–20 PubMedCrossRef

33.

Zulfiqar M, Yousem DM, Lai H (2013) ADC values and prognosis of malignant astrocytomas: does lower ADC predict a worse prognosis independent of grade of tumor? – a meta-analysis. AJR Am J Roentgenol 200(3):624–629 PubMedCrossRef

34.

Pope WB et al (2009) Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 252(1):182–189 PubMedCrossRef

35.

Pope WB et al (2011) Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol 32(5):882–889 PubMedCrossRef

36.

Provenzale JM et al (2004) Peritumoral brain regions in gliomas and meningiomas: investigation with isotropic diffusion-weighted MR imaging and diffusion-tensor MR imaging. Radiology 232(2):451–460 PubMedCrossRef

37.

Deng Z et al (2010) Quantitative analysis of glioma cell invasion by diffusion tensor imaging. J Clin Neurosci 17(12):1530–1536 PubMedCrossRef

38.

Rieger J et al (2010) Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol 99(1):49–56 PubMedCrossRef

39.

Mong S et al (2012) Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls. AJNR Am J Neuroradiol 33(9):1763–1770 PubMedCrossRef

40.

Raab P et al (2010) Cerebral gliomas: diffusional kurtosis imaging analysis of microstructural differences. Radiology 254(3):876–881 PubMedCrossRef

41.

Van Cauter S et al (2012) Gliomas: diffusion kurtosis MR imaging in grading. Radiology 263(2):492–501 CrossRef

42.

Reichenbach JR, Haacke EM (2001) High-resolution BOLD venographic imaging: a window into brain function. NMR Biomed 14(7–8):453–567

43.

Reichenbach JR et al (1997) Small vessels in the human brain: MR venography with deoxyhemoglobin as an intrinsic contrast agent. Radiology 204(1):272–277 PubMedCrossRef

44.

Kim HS et al (2009) Added value and diagnostic performance of intratumoral susceptibility signals in the differential diagnosis of solitary enhancing brain lesions: preliminary study. AJNR Am J Neuroradiol 30(8):1574–1579 PubMedCrossRef

45.

Park MJ et al (2009) Semiquantitative assessment of intratumoral susceptibility signals using non-contrast-enhanced high-field high-resolution susceptibility-weighted imaging in patients with gliomas: comparison with MR perfusion imaging. AJNR Am J Neuroradiol 30(7):1402–1408 PubMedCrossRef

46.

Deistung A et al (2013) Quantitative susceptibility mapping differentiates between blood depositions and calcifications in patients with glioblastoma. PLoS One 8(3):e57924 PubMedCentralPubMedCrossRef

47.

Radbruch A et al (2012) Differentiation of brain metastases by percentagewise quantification of intratumoral-susceptibility-signals at 3 Tesla. Eur J Radiol 81(12):4064–4068 PubMedCrossRef

48.

Lupo JM et al (2013) Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme. Neuro Oncol 15(4):480–489 PubMedCentralPubMedCrossRef

49.

Schweser F et al (2010) Differentiation between diamagnetic and paramagnetic cerebral lesions based on magnetic susceptibility mapping. Med Phys 37(10):5165–5178 PubMedCrossRef

50.

Radbruch A, Schlemmer HP (2013) Application of ultrahigh-field MRI in neuro-oncology. Radiologe 53(5):411–414 PubMedCrossRef

51.

Balchandani P, Naidich TP (2014) Ultra-high-field MR neuroimaging. AJNR Am J Neuroradiol [Epub ahead of print]

52.

Radbruch A, EidelO, Wiestler B et al (2015) Quantification of tumor vessels in glioblastoma patients using time-of-flight angiography at 7 Tesla: a feasibility study. Plos One 9(11):e110727 CrossRef

53.

Nagel AM et al (2011) The potential of relaxation-weighted sodium magnetic resonance imaging as demonstrated on brain tumors. Invest Radiol 46(9):539–547 PubMedCrossRef

54.

Nagel AM et al (2014) In vivo 35Cl MR imaging in humans: a feasibility study. Radiology 271(2):585–595 PubMedCrossRef

55.

Hoffmann SH et al (2014) Direct (17)O MRI with partial volume correction: first experiences in a glioblastoma patient. MAGMA 27(6):579–587 PubMedCrossRef

56.

Paech D et al (2014) Nuclear overhauser enhancement mediated chemical exchange saturation transfer imaging at 7 Tesla in glioblastoma patients. PLoS One 9(8):e104181 PubMedCentralPubMedCrossRef

57.

Zaiss M et al (2013) MR imaging of protein folding in vitro employing nuclear-Overhauser-mediated saturation transfer. NMR Biomed 26(12):1815–1822 PubMedCrossRef

Titel: Auf dem Weg zu mehr Präzision in der Hirntumortherapie
Möglichkeiten und Grenzen der MR-Bildgebung
verfasst von: Dr. A. Radbruch
E. Hattingen
Publikationsdatum: 01.06.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Der Nervenarzt / Ausgabe 6/2015
Print ISSN: 0028-2804
Elektronische ISSN: 1433-0407
DOI: https://doi.org/10.1007/s00115-015-4313-x

Neu in den Fachgebieten Neurologie und Psychiatrie

04.12.2023 | Praxismanagement | Nachrichten

Springer Medizin

Auf dem Weg zu mehr Präzision in der Hirntumortherapie

Möglichkeiten und Grenzen der MR-Bildgebung

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Systematisches Fehlermanagement bleibt die Ausnahme

Jahr 1 nach Hörsturz besonders gefährlich

Alzheimer-Demenz: Nutzen und Risiken von Donanemab unter der Lupe

Arbeit in der Anästhesie: Mehr als die Hälfte steht vor dem Burn-out

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2015

Die Sinusthrombose einer 15-Jährigen

Mechanische Thrombektomie bei akutem ischämischem Schlaganfall

Mitteilungen der DGN 6/2015

Primäre ZNS-Lymphome

Morbus Huntington

Fumarsäure oder Dimethylfumarat?

Neu in den Fachgebieten Neurologie und Psychiatrie

Systematisches Fehlermanagement bleibt die Ausnahme

Jahr 1 nach Hörsturz besonders gefährlich

Alzheimer-Demenz: Nutzen und Risiken von Donanemab unter der Lupe

Arbeit in der Anästhesie: Mehr als die Hälfte steht vor dem Burn-out